Tarek M.A. Abdel-Fatah
SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis
Abdel-Fatah, Tarek M.A.; Agarwal, Devika; Liu, Dong-Xu; Russell, Roslin; Rueda, Oscar M.; Liu, Karen; Xu, Bing; Moseley, Paul M.; Green, Andrew R.; Pockley, Alan G.; Rees, Robert C.; Caldas, Carlos; Ellis, Ian O.; Ball, Graham R.; Chan, Stephen Y.T.
Authors
Devika Agarwal
Dong-Xu Liu
Roslin Russell
Oscar M. Rueda
Karen Liu
Bing Xu
Paul M. Moseley
ANDREW GREEN ANDREW.GREEN@NOTTINGHAM.AC.UK
Associate Professor
Alan G. Pockley
Robert C. Rees
Carlos Caldas
Professor IAN ELLIS IAN.ELLIS@NOTTINGHAM.AC.UK
Professor of Cancer Pathology
Graham R. Ball
Stephen Y.T. Chan
Abstract
Background: Proliferation markers and profiles have been recommended for guiding the choice of systemic treatments for breast cancer. However, the best molecular marker or test to use has not yet been identified. We did this study to identify factors that drive proliferation and its associated features in breast cancer and assess their association with clinical outcomes and response to chemotherapy.
Methods: We applied an artificial neural network-based integrative data mining approach to data from three cohorts of patients with breast cancer (the Nottingham discovery cohort (n=171), Uppsala cohort (n=249), and Molecular Taxonomy of Breast Cancer International Consortium [METABRIC] cohort; n=1980). We then identified the genes with the most effect on other genes in the resulting interactome map. Sperm-associated antigen 5 (SPAG5) featured prominently in our interactome map of proliferation and we chose to take it forward in our analysis on the basis of its fundamental role in the function and dynamic regulation of mitotic spindles, mitotic progression, and chromosome segregation fidelity. We investigated the clinicopathological relevance of SPAG5 gene copy number aberrations, mRNA transcript expression, and protein expression and analysed the associations of SPAG5 copy number aberrations, transcript expression, and protein expression with breast cancer-specific survival, disease-free survival, distant relapse-free survival, pathological complete response, and residual cancer burden in the Nottingham discovery cohort, Uppsala cohort, METABRIC cohort, a pooled untreated lymph node-negative cohort (n=684), a multicentre combined cohort (n=5439), the Nottingham historical early stage breast cancer cohort (Nottingham-HES; n=1650), Nottingham early stage oestrogen receptor-negative breast cancer adjuvant chemotherapy cohort (Nottingham-oestrogen receptor-negative-ACT; n=697), the Nottingham anthracycline neoadjuvant chemotherapy cohort (Nottingham-NeoACT; n=200), the MD Anderson taxane plus anthracycline-based neoadjuvant chemotherapy cohort (MD Anderson-NeoACT; n=508), and the multicentre phase 2 neoadjuvant clinical trial cohort (phase 2 NeoACT; NCT00455533; n=253).
Findings: In the METABRIC cohort, we detected SPAG5 gene gain or amplification at the Ch17q11.2 locus in 206 (10%) of 1980 patients overall, 46 (19%) of 237 patients with a PAM50-HER2 phenotype, and 87 (18%) of 488 patients with PAM50-LumB phenotype. Copy number aberration leading to SPAG5 gain or amplification and high SPAG5 transcript and SPAG5 protein concentrations were associated with shorter overall breast cancer-specific survival (METABRIC cohort [copy number aberration]: hazard ratio [HR] 1·50, 95% CI 1·18–1·92, p=0·00010; METABRIC cohort [transcript]: 1·68, 1·40–2·01, p
Citation
Abdel-Fatah, T. M., Agarwal, D., Liu, D., Russell, R., Rueda, O. M., Liu, K., …Chan, S. Y. (2016). SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncology, 17(7), 1004-1018. https://doi.org/10.1016/S1470-2045%2816%2900174-1
Journal Article Type | Article |
---|---|
Acceptance Date | Jun 14, 2016 |
Online Publication Date | Jun 14, 2016 |
Publication Date | 2016-07 |
Deposit Date | Oct 19, 2016 |
Publicly Available Date | Mar 29, 2024 |
Journal | The Lancet Oncology |
Print ISSN | 1470-2045 |
Electronic ISSN | 1474-5488 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 17 |
Issue | 7 |
Pages | 1004-1018 |
DOI | https://doi.org/10.1016/S1470-2045%2816%2900174-1 |
Public URL | https://nottingham-repository.worktribe.com/output/975742 |
Publisher URL | http://www.sciencedirect.com/science/article/pii/S1470204516001741 |
Files
THELANCETONCOLOGY-D-15-01510R4.pdf
(2.2 Mb)
PDF
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: digital-library-support@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search